The angiotensin-converting enzyme insertion/deletion and the endothelin -134 3A/4A gene polymorphisms in patients with chronic plaque psoriasis

Experimental Dermatology

Volumn 16, Issue 12, 2007, Pages 993-998

  Weger, Wolfgang ^a   Hofer, Angelika ^a   Wolf, Peter ^a   El Shabrawi, Yosuf ^a   Renner, Wilfried ^a   Kerl, Helmut ^a   Salmhofer, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

ACE; Chronic plaque psoriasis; Endothelin 1; Gene polymorphism, risk factor

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; EXONUCLEASE; GENOMIC DNA;

5' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CHRONIC DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PSORIASIS VULGARIS;

ADULT; AGE OF ONSET; AGED; AUSTRIA; CASE-CONTROL STUDIES; ENDOTHELIN-1; FEMALE; HUMANS; INDEL MUTATION; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PSORIASIS;

EID: 36448981432     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2007.00620.x     Document Type: Article

References (57)

1. Christophers E. Psoriasis -epidemiology and clinical spectrum. Clin Exp Dermatol 2001: 26: 314-320.
2. Plant D, Young H S, Watson R E, Worthington J, Griffiths C E. The CX3CL1-CX3CR1 system and psoriasis. Exp Dermatol 2006: 15: 900-903.
3. Koks S, Kingo K, Vabrit K, et al. Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun 2005: 6: 407-415.
4. Reich K, Mossner R, König I R, Westphal G, Ziegler A, Neumann C. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1 beta are associated with different subtypes of psoriasis characterized by early and late onset disease. J Invest Dermatol 2002: 118: 155-163.
5. Asadullah K, Eskdale J, Wiese A, Gallagher G, Friedrich M, Sterry W. Interleukin-10 promoter polymorphism in psoriasis. J Invest Dermatol 2001: 116: 975-978.
6. Campalani E, Allen M H, Fairhurst D, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006: 154: 345-352.
7. Cohen A D, Bonneh D Y, Reuveni H, Vardy D A, Naggan L, Halevy S. Drug exposure and psoriasis vulgaris: Case-control and case-crossover studies. Acta Derm Venerol 2005: 85: 299-303.
8. Coulter D M, Pillans P I. Angiotensin-converting enzyme inhibitors and psoriasis. N Z Med J 1993: 106: 392-393.
9. Gilleaudeau P, Vallat V P, Carter D M, Gottlieb A B. Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J Am Acad Dermatol 1993: 28: 490-492.
10. Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica 1990: 181: 51-53.
11. Steckelings U M, Artuc M, Wollschlager T, Wiehstutz S, Henz B M. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venerol 2001: 81: 321-325.
12. Ehlers M R, Riordan J F. Angiotensin-converting enzyme: New concepts concerning its biological role. Biochemistry 1989: 28: 5311-5318.
13. Takahashi T, Taniguchi T, Okuda M, et al. Participation of reactive oxygen intermediates in the angiotensin II-activated signaling pathways in vascular smooth muscle cells. Ann NY Acad Sci 2000: 902: 283-287.
14. Kranzhofer R, Schmidt J, Pfeiffer C A, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999: 19: 1623-1629.
15. Yang H Y, Erdös E G, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochem Biophys Acta 1970: 214: 374-376.
16. Murphey L J, Gainer J V, Vaughan D E, Brown N J. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 2000: 102: 829-832.
17. Poblete M T, Reynolds N J, Figueroa C D, Burton J L, Muller-Esterl W, Bhoola K D. Tissue kallikrein and kininogen in human sweat glands and psoriatic skin. Br J Dermatol 1991: 124: 236-241.
18. Winkelmann R K. Total plasma kininogen in psoriasis and atopic dermatitis. Acta Derm Venerol 1984: 64: 261-263.
19. Kolosovsky E D. Evaluation of different treatment methods in patients with psoriasis and content of kallikrein and kallikreinogen in blood plasma. Dermatology 1994: 188: 140-141.
20. Hibino T, Izaki S, Kimura H, Izaki M, Kon S. Partial purification of plasma and tissue kallikreins in psoriatic epidermis. J Invest Dermatol 1988: 90: 505-510.
21. Schremmer-Danninger E, Hermann A, Fink E, Fritz H, Roscher A A. Identification and occurrence of mRNAs for components of the kallikrein-kinin system in human skin and in skin diseases. Immunopharmacology 1999: 43: 287-291.
22. Wolf R, Machtey I, Feverman E J, Creter D. The kallikrein-kinin pathway in psoriasis. Preliminary observations. Biomedicine 1981: 35: 77-78.
23. Tschöpe C, Schultheiss H P, Walther T. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: Role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol 2002: 39: 478-487.
24. Hayashi R, Yamashita N, Matsui S, et al. Bradykinin stimulates IL-6 and IL-8 production by human lung fibroblasts through ERK- and p38 MAPK-dependent mechanisms. Eur Resp J 2000: 16: 452-458.
25. Fritz H, Jochum M, Muller-Esterl W. Kinins 1925-2000. Biol Chem 2001: 382: 3-4.
26. Nickoloff B J, Nestle F O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004: 113: 1664-1675.
27. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990: 86: 1343-1346.
28. Chang Y C, Wu W M, Chen C H, Lee S H, Hong H S, Hsu L A. Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in Taiwan. Br J Dermatol 2007: 156: 642-645.
29. Ozkur M, Erbagci Z, Nacak M, Tuncel A A, Alasehirli B, Aynacioglu A S. Association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with psoriasis. Br J Dermatol 2004: 151: 792-795.
30. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990: 86: 1343-1346.
31. Tanaka C, Kamide K, Takiuchi S, et al. An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms. Hypertens Res 2003: 26: 301-306.
32. Kahaleh M B, Fan P S. Effect of cytokines on the production of endothelin by endothelial cells. Clin Exp Rheumatol 1997: 15: 163-167.
33. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992: 19: 753-757.
34. Levin ER. Endothelins. N Engl J Med 1995: 333: 356-363.
35. Bagnato A, Venuti A, Di Castro V, Marcante M L. Identification of ETA receptor subtype that mediates endothelin induced autocrine proliferation of normal human keratinocytes. Biochem Biophys Res Comm 1995: 209: 80-86.
36. Wilson S H, Simari R D, Lerman A. The effect of endothelin-1 on nuclear factor kappa B in macrophages. Biochem Biophys Res Commun 2001: 286: 968-972.
37. Browatzki M, Schmidt J, Kubler W, Kranzhofer R. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 2000: 95: 98-105.
38. Bonifati C, Mussi A, Carducci M, et al. Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm Venerol 1998: 78: 22-26.
39. Trevisan G, Stinco G, Grisante C, Fiotti N, Vidamari P, Kokelj F. Psoriasis and endothelins. Acta Derma Venerol 1994: 186: 139-140.
40. Cecchi R, Giomi A, Ciuti M, Gironi A, Seghieri G. Increased levels of plasma endothelin-1 in patients with psoriasis. Clin Chim Acta 1994: 226: 113-115.
41. Yildiz L, Akcay F, Aktas A, Yildiz F, Sahin Y N. Increased concentrations of plasma endothelin-1 and fibronectin in psoriasis. Acta Derm Venerol 1997: 77: 166-167.
42. Zachariae H, Heickendorff L, Bjerring P. Plasma endothelin in psoriasis: possible relations to therapy and toxicity. Acta Derm Venerol 1996: 76: 442-443.
43. Popowski K, Sperker B, Kroemer H K, et al. Functional significance of a hereditary adenine insertion variant in the 5′-UTR of the endothelin-1 gene. Pharmacogenetics 2003: 13: 445-451.
44. Köppel H, Renner W, Gugl A, et al. The angiotensin-converting-enzyme insertion/deletion polymorphism is not related to venous thrombosis. Thromb Haemost 2004: 91: 76-79.
45. Tiret L, Rigat B, Visvikis S, et al. Evidence from combined segregation and linkage analysis that a variant of ACE gene controls plasma ACE levels. Am J Hum Genet 1992: 51: 197-205.
46. Ryder K W, Epinette W W, Jay S J, Ransburg R C, Glick M R. Serum angiotensin converting enzyme activity in patients with psoriasis. Clin Chim Acta 1985: 153: 143-146.
47. Huskic J, Alendar F, Matavulj A, Ostoic L. Serum angiotensin converting enzyme in psoriasis. Med Arh 2004: 58: 202-205.
48. Raff M, Bardach H, Müller M M. Angiotensin-converting enzyme (ACE) Increased serum activities in dermatological diseases. Arch Dermatol Res 1981: 270: 341-345.
49. Scholzen T E, Luger T A. Neutral endopeptidase and angiotension-converting enzyme - key enzymes terminating the action of neuroendocrine mediators. Exp Dermatol 2004: 13 (Suppl. 4): 22-26.
50. Kanda N, Watanabe S. Substance P enhances the production of interferon-induced protein of 10kDa by human keratinocytes in synergy with interferon-γ. J Invest Dermatol 2002: 119: 1290-1297.
51. Quinlan K L, Song I S, Bunnett N W, et al. Neuropeptide regulation of human dermal microvascular endothelial cell ICAM-1 expression and function. Am J Physiol 1998: 275: C1580-C1590.
52. Maggi C A. The effects of tachykinins on inflammatory and immune cells. Regul Pept 1997: 70: 75-90.
53. O'Connor T M, O'Connell J, O'Brien D I, Goode T, Bredin C P, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004: 21: 167-180.
54. Eedy D J, Johnston C F, Shaw C, Buchanan K D. Neuropeptides in psoriasis: An immunocytochemical and radioimmunoassay study. J Invest Dermatol 1991: 96: 434-438.
55. Naukkarinen A, Nickoloff B J, Farber E M. Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J Invest Dermatol 1989: 92: 126-129.
56. Chan J, Smoller B R, Raychauduri S P, Jiang W Y, Farber E M. Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 1997: 289: 611-616.
57. Jiang W Y, Raychaudhuri S P, Farber E M. Double-labeled immunofluorescence study of cutaneous nerves in psoriasis. Int J Dermatol 1998: 37: 572-574.